EPRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EP

Mkt Cap

$437.4M

Volume

568.48K

Next Earnings

November 3rd

Loading chart

EP

EPRXEupraxia Pharmaceuticals Inc. Common Stock

EPRX

Pay with—

Available Balance0.00

EP

Mkt Cap

$447.3M

Volume

568.48K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesEupraxia Pharmaceuticals announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE) have been accepted for presentation at the ACG 2026 Annual Scientific Meeting in Nashville (October 9-14) and UEG Week 2026 in Barcelona (October 17-20). The presentations will showcase data on improvements in dysphagia and histopathological features persisting over 52 weeks during dose escalation. Phase 2b interim data is expected in December 2026.GlobeNewswire Inc. · Oct 9, 2026

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic EsophagitisEupraxia Pharmaceuticals announced positive 52-week data from its Phase 1b/2a RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE). The highest dose cohorts demonstrated durable symptom responses with 64% of patients maintaining clinical remission at 52 weeks, meaningful histologic improvements, and a favorable safety profile with no serious adverse events or oropharyngeal candidiasis reported. The company plans to report Phase 2b interim data in December 2026.GlobeNewswire Inc. · Sep 30, 2026

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of ShareholdersEupraxia Pharmaceuticals held its Annual General Meeting on June 18, 2026, where all seven board nominees were elected with strong shareholder support. The company also re-appointed KPMG LLP as auditor. Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release products using its proprietary Diffusphere™ technology, with current programs in pain management and inflammatory gastrointestinal disease.GlobeNewswire Inc. · Jun 19, 2026

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual MeetingEupraxia Pharmaceuticals announced it will present 4 abstracts at Digestive Disease Week (May 2-5, 2026) showcasing clinical data from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis. The presentations include an oral presentation on dose escalation leading to persistent histological improvements over 36 weeks, plus three poster presentations on endoscopic features, dysphagia improvements, and dose optimization. The company will also host a virtual investor event discussing esophageal strictures and EP-104GI's potential.GlobeNewswire Inc. · Apr 22, 2026

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic EsophagitisEupraxia Pharmaceuticals announced positive 36-week data from the highest dose cohort (Cohort 9) of its Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis. The trial showed robust tissue health improvements with 90% reduction in EoEHSS Stage and 72% reduction in Peak Eosinophil Count, along with 66% clinical remission rate in symptoms. The drug demonstrated excellent safety with no serious adverse events reported across 31 patients and over 230 patient-months of follow-up. Phase 2b placebo-controlled results are expected in Q4 2026.GlobeNewswire Inc. · Apr 21, 2026

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsightThe US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.GlobeNewswire Inc. · Apr 13, 2026

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial ResultsEupraxia Pharmaceuticals announced the closing of a $63.2 million public offering and reported Q4 2025 financial results. The company achieved clinical milestones with its lead program EP-104GI in eosinophilic esophagitis, demonstrating positive tissue health data. Cash reserves increased to $80.5 million, with runway extending into the second half of 2028. However, net losses increased to $16.7 million in Q4 2025 compared to $7.5 million in Q4 2024, driven by higher R&D and administrative costs.GlobeNewswire Inc. · Mar 13, 2026

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter OptionEupraxia Pharmaceuticals successfully closed a $63.2 million public offering, including the full exercise of underwriter options. The company will use proceeds to advance EP-104GI for eosinophilic esophagitis through Phase 2 and Phase 3 clinical trials, expand pipeline candidates in additional gastrointestinal indications, and support commercial readiness preparations.Benzinga · Feb 20, 2026

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded WarrantsEupraxia Pharmaceuticals priced a US$55 million public offering of common shares at US$7.00 per share and pre-funded warrants at US$6.99999 per warrant. The company plans to use proceeds primarily for advancing EP-104GI for Eosinophilic Esophagitis through Phase 2 clinical trials and Phase 3 preparations, as well as expanding into additional gastrointestinal indications. The offering is expected to close on February 20, 2026.GlobeNewswire Inc. · Feb 19, 2026

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersEupraxia Pharmaceuticals announced the results of its Annual General and Special Meeting of Shareholders, where all six proposed directors were elected, and other business items were approved by shareholders.GlobeNewswire Inc. · Jun 2, 2025

to start trading

EP

EPRXEupraxia Pharmaceuticals Inc. Common Stock

EPRX

Pay with—

Available Balance0.00

Your PositionYou don't own any EPRX yet.

Related Tickers

Earnings